VX-702 is a highly specific p38alpha MAPK inhibitor, 14-fold higher selectivity for the p38alpha than p38beta. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
Molecular Weight:
404.32
Purity:
98.96%
CAS Number:
[745833-23-2]
Formula:
C19H12F4N4O2
Target:
Autophagy|||p38 MAPK
T2513
* VAT and and shipping costs not included. Errors and price changes excepted